Blog Posts
Detroit News Op-Ed: Preserving Michigan’s Competitive Bioscience Industry
In a recent op-ed for the Detroit News, Stephen Rapundalo, President and CEO of PULSE Partner MichBio, highlights the vital role of mergers and acquisitions (M&A) in fueling innovation and competition across Michigan’s life sciences ecosystem.
Forbes Commentary: Trump Administration Should Reverse “Anti-Merger” Approach to M&A
The culmination of flawed antitrust policies by the Federal Trade Commission (FTC) and Department of Justice (DOJ) have discouraged pro-competitive mergers that could meaningfully benefit American consumers – a growing concern raised by former FTC general counsel and antitrust expert Alden Abbott in his recent Forbes commentary, “Time for a Merger Reset.”
Innovations Advanced by M&A: New Treatment Options for Migraines
For many small and early-stage life science companies, making the leap from research and development (R&D) to manufacturing and distribution of a new treatment can be an insurmountable barrier. Pfizer’s acquisition of Biohaven Pharmaceuticals, for example, accelerated the global distribution of two new migraine therapies, while also allowing the early-stage company to continue pursuing new scientific breakthroughs.
CBSA: Life Sciences M&A Fuels Growth & Innovation in Colorado
In a recent blog post, PULSE partner Colorado Bioscience Association (CBSA) highlighted the fundamental role of pro-innovation mergers and acquisitions in driving life sciences innovation and economic growth in Colorado and beyond.
Latest Estimates Reinforce Burden of FTC’s Final HSR Rule
The Federal Trade Commission (FTC)’s recently finalized Hart-Scott-Rodino (HSR) premerger notification rule places a significant time and cost burden on companies engaging in pro-competitive mergers and acquisitions (M&A), according to top legal analyses and the Agency’s own estimates.
National Venture Capital Association: FTC’s Enforcement Approach is Chilling Critical Investment in New Breakthroughs
The Federal Trade Commission (FTC)’s aggressive approach to mergers and acquisitions enforcement (M&A) is disrupting critical investment in innovation, according to National Venture Capital Association (NVCA) President Bobby Franklin, in an interview with Axios.
What They Are Saying: FTC’s Final HSR Premerger Rules Place Undue Burden on Competitive M&A Across Life Sciences
Leading organizations are expressing concern about the impact of the Federal Trade Commission (FTC)’s final Hart-Scott-Rodino (HSR) premerger notification rule, including the chilling effect it could have on biopharmaceutical and life sciences innovation.
PULSE Campaign Statement on Final HSR Rules
The Partnership for the U.S. Life Science Ecosystem (PULSE) in response to the final Hart-Scott-Rodino (HSR) premerger notification rules released today by the Federal Trade Commission (FTC).
Bloomberg Law: “Chilling Effect” of FTC & DOJ’s Aggressive M&A Enforcement Approach
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive deals that pose no antitrust harms.
Innovations Advanced by M&A: A First-In-Class Treatment for Hypertrophic Cardiomyopathy
Mergers and acquisitions (M&A) are a vital mechanism for transitioning treatments currently in development to approved medicines available to the patients who need them the most. In one such example, the synergies from a life science acquisition brought a revolutionary therapy for hypertrophic cardiomyopathy (HCM) to patients.